None listed
Conditions
Interventions
None listed
Sponsors
Korea University Ansan Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: ° Patients with type 2 diabetes aged 19 to 80 years ° Those who will be treated with the following medicines among patients who are receiving or are scheduled to initiate insulin multiple daily injections (MDI) Type and product name of insulin - Basal insulin: Levemir, Lantus, Tresiba, Toujeo - Prandial insulin: NovoRapid, Fiasp, Humalog, Apidra - Mixed insulin : Ryzodeg ° Hypoglycemic agents other than insulin - Metformin, Thiazolidinedione (Pioglitazone, Lobeglitazone, Rosiglitazone), Sulfonylurea (Glimepiride, Gliclazide, Glipizide, Glibenclamide), Meglitinide (Repaglinide, Nateglinide, Mitiglinide), DPP4 inhibitor (Sitagliptin, Linagliptin, Gemigliptin, Vildagliptin, Saxagliptin, Alogliptin, Teneligliptin, Anagliptin, Evogliptin), GLP-1 agonist (Exenatide, Lixisenatide, Liraglutide, Exenatide LAR, Albiglutide, Dulaglutide), SGLT-2 inhibitor (Dapagliflozin, Empagliflozin, Ipragliflozin), a-glucosidase Inhibitor (Acarbose, Voglibose) ° Fasting C-peptide level measured at the hospital in the past 2 years is 0.4-3.0ng/mL.
Exclusion criteria
Exclusion criteria: Those who fall under any of the following criteria ° Insulin pump users ° Those who have been hospitalized for HHS (hyperglycemia hyperosmolar syndrome), DKA (Diabetic ketoacidosis), acute myocardial infarction, or stroke in the past 3 months ° Stage 4 or 5 of chronic renal disease (< eGFR 30) ° Patients with hepatic failure (AST or ALT = 2.5 times the upper normal limit) or symptomatic heart failure with pulmonary oedema ° Those who are currently receiving anticancer therapy, radiation therapy, and targeted therapy ° Those who are currently receiving the following medicines that may affect blood glucose - Steroid, immunosuppressive agents (cyclosporine, tacrolimus, and sirolimus), nicotinic acid =1500mg/day, systemic isotretinoin, and anti-obesity agents (liraglutide, orlistat, phentermine, phendimetrazine, mazindol) - Route of steroid administration: Oral administration and intravenous injection and joint injection are excluded from the study (A nasal spray or inhaler at maintenance dose may be used in this study) ° Patients with uncontrolled hypertension (SBP =160 mmHg or DBP =100 mmHg) ° Pregnant or lactating women ° Those who are determined to be not eligible for this study in the judgment of the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| odds ratio for hypoglycemia during continuous glucose monitoring | — |
Secondary
| Measure | Time frame |
|---|---|
| Odds ratio between glucose variability and diabetes complications (diabetic retinopathy, renal disease, and neuropathy);Odds ratio between glucose variability and cardiovascular disorders;Correlation between glucose variability and insulin resistance;Correlation between glucose variability and heart rate variability;Correlation between glucose variability and muscle mass;correlation between glucose variability and blood pressure variability.;correlation between glucose variability and heart function. | — |
Countries
Korea, Republic of
Contacts
Public ContactYun Ah Kim
Korea University Ansan Hospital
Outcome results
None listed